Copy Link Print Information

Molnupiravir

(Synonyms: EIDD-2801; MK-4482)
74 Cited Publications
Avis client

Based on 74 publication(s) in Google Scholar

Molnupiravir (EIDD-2801) is an orally bioavailable proagent of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

  • Pureté: 99.85%
  • CAS No.: 2492423-29-5
  • Formule: C13H19N3O7
  • Masse moléculaire:329.31
  • Stockage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Molnupiravir Chemical Structure
    Molnupiravir Chemical Structure
  • Experimental Validation Results for Molnupiravir
  • Experimental Validation Results for Molnupiravir
  • Experimental Validation Results for Molnupiravir
  • Experimental Validation Results for Molnupiravir
  • Experimental Validation Results for Molnupiravir
CAS No.: 2492423-29-5
Size
Prix
Stock
Quantité
Amount: USD 0.00
Please select quantity
or
or

* Veuillez sélectionner la quantité avant d'ajouter des articles.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Molnupiravir:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Trouvez votre distributeur local Your local distributor: Hycultec GmbHHycultec
  • Activité biologique
  • Chemical Information
  • Solvant et solubilité
  • Pureté et documentation
  • Références
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Molnupiravir

More
Customer Validation & Images
In Vivo Efficacy StudyBio/Physico-chemical AssayIHC
  • In Vivo Efficacy Study
  • Bio/Physico-chemical Assay
  • In Vivo Efficacy Study
  • IHC
  • In Vivo Efficacy Study
Keywords
100 mg

Obtenir un devis En stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Enregistrer
Sign in to MedChemExpress
Enregistrer un nouveau compte

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Molnupiravir Chemical Structure
    Molnupiravir Chemical Structure
    1/16
  • 1/16

    Molnupiravir purchased from MedChemExpress. Usage Cited in: Nature. 2022 Jul;607(7917):119-127. [Abstract]

    Customer Validation
     Syrian hamsters were intranasally inoculated with 103 PFU of BA.2 (NCD1288). One day after infection, hamsters were treated with: 500 mg/kg Molnupiravir, 1,000 mg/kg nirmatrelvir or 60 mg/kg S-217622 orally twice daily for 3 days. Methylcellulose served as a control for oral treatment. Eight hamsters per group were euthanized at 4 dpi for virus titration. Viral titres in the nasal turbinates and lungs were determined by plaque assay. For comparison of the lung and nasal turbinate titres of BA.2 (NCD1288)-and D614G (HP095)-infected hamster groups, we used a Kruskal-Wallis test with Dunn's multiple comparisons and one-way ANOVA with Dunnett's multiple comparisons, respectively. Data are from one experiment.

  • 1/16

    Molnupiravir purchased from MedChemExpress. Usage Cited in: Nature. 2022 Apr;604(7904):134-140. [Abstract]

    Customer Validation
     BLISS analysis in Calu-3 cells with molnupiravir or remdesivir in combination with the DHODH inhibitors Brequinar.

  • 1/16

    Molnupiravir purchased from MedChemExpress. Usage Cited in: Nature. 2022 Apr;604(7904):134-140. [Abstract]

    Customer Validation
     Wild-type BALB/C mice were treated with Brequinar (intraperitoneal administration) and/or Molnupiravir (oral administration) daily at the indicated concentrations starting 12 h before infection. Mice (n = 5 per group over 2 independent experiments) were intranasally inoculated with 1 × 105 p.f.u. per mouse of SARS-CoV-2 (B.1.351). Lungs were analysed for viral titre 2 days after infection by plaque assay.

  • 1/16

    Molnupiravir purchased from MedChemExpress. Usage Cited in: Nature. 2022 Apr;604(7904):134-140. [Abstract]

    Customer Validation
     Wild-type BALB/C mice were treated with Brequinar (intraperitoneal administration) and/or Molnupiravir (oral administration) daily at the indicated concentrations starting 12 h before infection. Mice (n = 5 per group over 2 independent experiments) were intranasally inoculated with 1 × 105 p.f.u. per mouse of SARS-CoV-2 (B.1.351). Fixed in 4% paraformaldehyde for haematoxylin and eosin staining and quantified for interstitial inflammation.

  • 1/16

    Molnupiravir purchased from MedChemExpress. Usage Cited in: Nat Microbiol. 2022 Aug;7(8):1252-1258. [Abstract]

    Customer Validation
     Syrian hamsters were intranasally inoculated with 103 PFU of BA.1 (NC928). At 24 h post-infection, hamsters were treated with: 500 mg/kg Molnupiravir orally twice daily for 3 days or 60 mg/kg S-217622 orally twice daily for 3 days. Methylcellulose served as a control for oral treatment. Hamsters were euthanized on Days 2, 3, and 4 post-infection for virus titration. Vertical bars show the mean ± s.e.m. Points indicate data from individual hamsters (n = 4/group).

  • Molnupiravir